NASDAQ: FNCHFinch Therapeutics Group Inc Stock
$5.88-0.20 (-3.29%)
Updated Sep 22, 2023
FNCH Price
$5.88
Fair Value Price
N/A
Market Cap
$9.44M
52 Week Low
$5.48
52 Week High
$60.00
P/E
-0.07x
P/B
0.34x
P/S
54.11x
PEG
N/A
Dividend Yield
N/A
Revenue
$253.00k
Earnings
-$138.27M
Gross Margin
100%
Operating Margin
-56,473.52%
Profit Margin
-54,651.4%
Debt to Equity
1.4
Operating Cash Flow
-$56M
Beta
0.93
Next Earnings
N/A
Ex-Dividend
N/A
Next Dividend
N/A
FNCH Overview
Finch Therapeutics Group, Inc., a clinical-stage microbiome therapeutics company, develops a novel class of orally administered drugs in the U.S. The company collaborates and has license agreements with Takeda Pharmaceutical Company Ltd, Skysong Innovations LLC, and the University of Minnesota. The company was incorporated in 2014 and is based in Somerville, MA.
Zen Score
–
Industry Average (25)
You've viewed Zen Score for 10/10 free stocks. Upgrade to Premium to see how FNCH scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.
Due Diligence Checks
FNCH is unprofitable, so we are unable to calculate its intrinsic value according to an updated version of Benjamin Graham's Formula from "The Intelligent Investor"
Below Benjamin Graham Formula Value Valuation
FNCH is good value based on its book value relative to its share price (0.34x), compared to the US Biotechnology industry average (5.11x)
P/B vs Industry Valuation
FNCH is unprofitable, so we... subscribe to Premium to read more.
PEG Value Valuation
There are 30 more FNCH due diligence checks available for Premium users.
Be the first to know about important FNCH news, forecast changes, insider trades & much more!
FNCH News
Valuation
FNCH price to earnings (PE)
For valuing profitable companies with steady earnings
Company
-0.07x
Industry
12.89x
Market
14.52x
FNCH price to book (PB)
For valuing companies that are loss-making or have lots of physical asset
Company
0.34x
Industry
5.11x
FNCH is good value based... subscribe to Premium to read more.
P/B vs Industry Valuation
FNCH's financial health
Profit margin
Revenue
$0.0
Net Income
-$7.0M
Profit Margin
0%
FNCH's cash and short-term investments... subscribe to Premium to read more.
Interest Coverage Financials
FNCH's profit margin has decreased... subscribe to Premium to read more.
Profit Margin Growth Financials
Assets to liabilities
Assets
$66.9M
Liabilities
$39.0M
Debt to equity
1.4
FNCH's short-term assets ($36.50M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
FNCH's short-term assets ($36.50M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
FNCH's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials
Cash flow
Operating
-$9.2M
Investing
$1.3M
Financing
$4.0k
FNCH's cash and short-term investments... subscribe to Premium to read more.
Debt Coverage Financials
FNCH vs Biotech Stocks
Finch Therapeutics Group Stock FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.